Abstract-MK-801, a non-competitive antagonist of N-methy&aspartate-type glutamate receptors, was tested for its abiiity to antagonize excitotoxic actions of ~-methyl-~-as~~ate or quisqualic acid injected into the brains of seven-day-old rats, Stereotaxic injection of ~"me~yi-~aspa~ate (25 nmol/OS ai) or quisqualic acid (100 nmol/l.O ~1) into the corpus striatum under ether anesthesia consistently produced severe unilateral neuronal necrosis in the basal ganglia, dorsal hippocampus and overlying neocortex. The distribution of the damage corresponded to the topography of glutamate receptors in the vulnerable regions demonstrated by previous autoradiographic studies, ~-Methyl-~aspa~ate produced severe, mntluent neuronal destruction while quisquaiic acid typicatty caused more selective neuronaf necrosis. The data indicate that systemic admin~stra~on of MK-8Of can prevent ~-methyl-D-aspar~te-indu~ neuronal injury in perinatsl rat brain even when administered after the initial insult. MK-801 also partially antagonized quisqualic acid-mediated neurotoxicity, suggesting that quisqualic acid-induced toxicity is, in part, mediated through N-methyl+aspartate receptor activation. The sensitivity of the developing brain to the toxicity of N-methyl-D-aspartate provides a sensitive and reproducible in uivo model for exploring these issues and for screening prospective neuroprot~tive drugs that act at the N-methyl-Daspartate receptor-channel complex.
Abstract-MK-801, a non-competitive antagonist of N-methy&aspartate-type glutamate receptors, was tested for its abiiity to antagonize excitotoxic actions of ~-methyl-~-as~~ate or quisqualic acid injected into the brains of seven-day-old rats, Stereotaxic injection of ~"me~yi-~aspa~ate (25 nmol/OS ai) or quisqualic acid (100 nmol/l.O ~1) into the corpus striatum under ether anesthesia consistently produced severe unilateral neuronal necrosis in the basal ganglia, dorsal hippocampus and overlying neocortex. The distribution of the damage corresponded to the topography of glutamate receptors in the vulnerable regions demonstrated by previous autoradiographic studies, ~-Methyl-~aspa~ate produced severe, mntluent neuronal destruction while quisquaiic acid typicatty caused more selective neuronaf necrosis. Intraperitoneal administration of MK-801 (0.1-1.0 mg/kg) 30 min before N-methyl-D-aspartate injection had a prominent dose-dependent neuroprotective effects as assessed morphometrically by comparison of bilateral striatal, hippocampal and cerebral hemisphere cross-sectional areas five days later. A 1 mg/kg dose of MK-801 given as pre-treatment completely protected the infant brain. The same dose of MK-801 was also completely protective when administers 30 or 40 min after ~-methyl-~-as~rtate and afforded partial protection when given 2 h later. MK-801 pre-treatment also prevented the electrically confirmed behavioral seizures induced by N-methyl-D-aspartate. The drug significantly reduced striatal but not hippocampal or neocortical injury when given as two doses (I mg/kg) 30 min prior to and immediately following quisqualic acid injection.
The data indicate that systemic admin~stra~on of MK-8Of can prevent ~-methyl-D-aspar~te-indu~ neuronal injury in perinatsl rat brain even when administered after the initial insult. MK-801 also partially antagonized quisqualic acid-mediated neurotoxicity, suggesting that quisqualic acid-induced toxicity is, in part, mediated through N-methyl+aspartate receptor activation. The sensitivity of the developing brain to the toxicity of N-methyl-D-aspartate provides a sensitive and reproducible in uivo model for exploring these issues and for screening prospective neuroprot~tive drugs that act at the N-methyl-Daspartate receptor-channel complex.
The excitatory amino acid @AA) receptor subtypes, specific for IV-methyl-D-aspartate (NMDA), quisqualate and kainate are uniquely distributed in the developing and mature brain and are distinguished by biochemical,i5v24*2s electrophysiologicalS.~o,3s,52 and pharmacological criteria.8.'8~19*37 Each of the receptor subtypes may mediate physiologic excitatary neuronal responses but under conditions of excessive receptor activation, agonists for these receptors are capable of initiating a cascade of events resulting in neuronal death in both the adult39*42.M and immature brain.7*33"h49 The NM~A-prefer~ng receptor subtype has been best characterized el~trophysiolog~ca~~y __I.. fiTo wham correspondence should be addressed.
Abbreufatfons:
APN, 7-~~nophosphonoh~~noic acid; EAA, excitatory amino acid; EEG, eleetroencephaiogram; MK-801, f( +)-5-methyl-iO,I i-dihydro-5I%di-benzo[a,dicycloheaten-5, IO-imine meleatel: NMDA. N-meihyl:D-aspariate; PBF, phosphate-buf&red forma; lin; PBS, phosphate-buffered saline. and biochemicalfy (for review see Ref. 8) . NMDA activates a calcium-permeable cationic channel26 that is gated by Mg2+ 30*40 in a voltage-dependent manner.1t,27 The NMDA response is enhanced by glycine22 and is non-competitively blocked in a usedependent manner by phencyclidine receptor ligands including (( + )-Smethyt-10,l I -dihydro-SH-dibenzo~~~~~y~Iohepten-~,~O-i~ne meleate) (MK-S01)6 and the dissociative anesthetic ciass of compounds.29*'4 Furthermore, the distributions of NMDA and phencyclidine receptors in the mammalian forebrain are identical." This finding, taken together with pharmacological evidence of interactions between these two receptor sites, suggests that NMDA and phencyclidine receptors may be components of the same receptor-ion channel complex.
Excessive 
EXPERIMENTAL PROCEDURES
Seven-day-old male and female Sprague-Dawley albino rat pups (Charles River, MI), maintained on a 12 h:l2 h 1ight:dark cycfe, were used for these experiments and were housed with the dam at all times except for a 2-h experimental period. lntracerebral injections of excitotoxins were performed in seven-day-old pups briefly but deeply anesthetized with ether.l" A midline cranial incision was made through the skin to expose the calvarium. Drugs were administered under stereotaxic guidance (Kopf small animal apparatus) using a Hamilton syringe with a 26-gauge needle. Pups were positioned in a plaster of Paris mold of the head and body. All intracerebral injections were directed into the posterior corpus striatum. Coordinates were AP 2.0mm, ML 2.5 mm, at depth of 4.0 mm from the dura using bregma as a landmark. The needle was left in place for 2min following injections to limit leakage.
EEG signals from each hemisphere were recorded simultaneously. Signals were amplified by a total gain of 20,000. Active filters limited the signal to I-40 Hz. EEG signals were digitized and stored on magnetic tape. Representative lo-min sements were printed. EEGs were recorded in four Drugs were dissolved in 0.01 M Tris. pH 7.4. Pups received either NMDA (25 nmol/O.S pl), quisqualic acid (100 nmol/I.O pt) or vehicle (OS ~1) in~astri~tali~, MK-801 dissolved in ohosohate-buffered saline (PBS, pH 7.4) was injected intra'peritbneally (i.p.) in 0.05 ml. Control animals received equal volumes of PBS.
Two groups of MK-801 treatment protocols were used to assess neuroprot~tion using NMDA: (I) administration of a single dosage of MK-801 CO. 1,0.25, 0.5, I .O mg/kg; n = 9. 7. 13. 8. resoectivelv) 30 min prior to intrastriatal NMDA injection: (i) a single dose -(l mg/kg) at different time intervals in relation to NMDA iniection (-30, +30, 40. 120 min; n = 8, 5, 5, 6. respe&ely) .
A third protocol was used in which two doses of MK-801 were administered ~.
^ . . .* (each I mg/kg), the tirst 30 mm betore and another Immeol-~ _ ~, _ ,, or treatment groups: int&striataI NMDA alone (n = 5). i.p. MK-801 (1 mg/kg) 30min prior to intrastriatal NMDA (n = 5). i.p. MK-801 alone (n = 5), and untreated controls (n = 5). Recordings were made from pups at I (n = 3) and 4 (n = 2) h after intrastriatal injection of NMDA. Statistical comparisons consisted of two-tailed independent f-tests when two groups were compared and one-way ANOVA when multiple comparisons were made. Twoway ANOVAs were used when comparisons were made between groups with two variables (Systat, Evanston, IL). The dependent variable in all tests was percentage damage (C -l/C\. extent where noted otherwise. ately following intrastriatal quisqualic acid administration (n = 6). Four-additional groips served as controls: intrastriatal NMDA + in. PBS (n = 28). intrastriatal vehicle + i.p. PBS (n = S), intiastriatal vehicle + i.p. MK-801 (n = 7) and intrastriatal quisquaiic acid f i.p. PBS (n = 4). Appropriate littermate controls were included in each experiment on each day.
All pups were subsequently returned to the dam for five days and were decapitated on day 12. A five-day survival period allows sufficient time for brain edema to resolve (unpublished obseffatjons).
Their brains were removed and placed sequentially into 10% phosphatebuffered formalin (PBF) followed by a 30% sucrose/PBF solution. Fifty-micron frozen microtome coronal sections were stained for Nissl substance with Cresyl Violet. Tissue damage was assessed qualitatively by light microscopy and quantitated by measurement of cross-sectional areas of corpus striatum, dorsal hippocampus and cerebral hemisphere using a video-based computer-aided image analyser. For each animal, measurements were made bilaterally in four coronal sections through each individual structure corresponding to 0.7, 1.0. 1.3, 1.6 mm (striatum, cerebral hemisphere) and 2.6. 2.8, 3.0, 3.2 mm (hippocampus) caudal to bregma. The four measures for each structure were summed within animals by hemisphere and transformed by the formula 100 x (C -l/C) into a term reflecting the degree of damage (% damage) of the structure in the injected hemisphere relative to the contralateral structure. C and I refer to the cross-sectional areas of anatomical structures contralateral (C)and ipsilateral (I) to the lesioned hemisphere. The data were expressed as percentage protection (mean + S.E.M.) for each experimental group using the following formula:
Values for experimental groups that received MK-801 and an excitotoxin were compared with control groups that received an excitotoxin and saline.
Cortical electroencephalograms (EEGs) were recorded from seven-day-old rat pups at 1 (n = 12) and 4 (n = 8) h after intracerebral injections of 25 nmoi/0.5 ,ul of NMDA. EEG activity was recorded jnde~ndently from each cerebral hemisphere. To prepare pups for EEG recordings, they were briefly anesthetized with ether, the scalp was incised in the midline and five holes were made into the skull with a 26-gauge needle. Using bregma as a central landmark, electrodes were placed bilaterally at AP + 3.75 mm. ML 2.5 mm and AP -3.Xmm, ML 2Smm. and the ground was placed at a fifth site anteriorally and adjacent to the midline. Electrodes were secured at the epidural surface of the cortex with dental acrylic.
Electrodes were connected to a Grass P5 11 J amplifier and Materials NMDA, quisqualic acid and other chemicals were obtained from Sigma (St Louis, MO). MK-801 was a gift from Dr P. Anderson (Merck, Sharp and Dohme, West Point, PA).
RESULTS

Histological signs of N-methyl-D-aspartate neurotoxicity
Intracerebral
NMDA injections into seven-day-old rats consistently produced extensive cellular necrosis, prominent gliosis, tissue loss and hemisphere deformity on the injected side when examined five days later (Fig. 1) . Neuronal destruction was confluent in glutamate receptor-rich regions and within or directly adjacent to the injection site: corpus striatum, dorsal hippo~ampus and overlying neocortex. Tissue damage was always confined to the injected hemisphere and there appeared to be no microscopic signs of neuronal injury in the contralateral hemisphere. Other anatomical regions showing evidence of neuronal destruction included the lateral septal nuclei, septofimbrial nucleus, thalamic nuclei (ventral posterior medial, ventral posterior lateral, lateral dorsal ventrolateral, reticular), entopeduncular nucleus, and the subthalamic nucleus. More selective neuronal destruction was seen at the borders of the lesion and certain substructures were more vulnerable than others. For example, within the hippocampal subfields a hierarchical order of susceptibility to NMDA toxicity existed, CA3 > CA1 > CAZ, and the dentate gyrus was relatively spared (especially the ventral blade). The cerebral cortical layers I-III were relatively resistant to NMDA toxicity. Selectivity in these cortical layers did not appear to reflect the distance from the injection site since direct intracortical injections of NMDA produced similar selective laminar necrosis (data not presented). The globus pallidus was partially resistant to intrastriatal NMDA injection with sparing of its intrinsic large multipolar neurons. This is consistent with the relative lack of NMDA receptors in this structure." Other areas near the lesion which were unaffected included the nucleus accumbens, basolateral amygdala, cingulum and anterior commissure. Intrastriatal injection of vehicle did not produce any apparent signs of neuronal injury. Neuroprotective efSect qf MK-801 (I mg/kg) given 30 min priar to intrastriatal NMDA (25 nmol/0.5 ~1) protected completely against both the gross and microscopic features of its neurotoxicity (Fig. I) , Neuroprotective et%cts of varying doses of MK-801 on neurotoxicity of a fixed dose of NMDA are illustrated in coronal sections through the striatum (Fig. 2) and h~ppocampus (Fig. 3) . Confluent necrosis, neuronal destruction, gross tissue deformation and widening of the ipsilateral ventricle were evident in animals pre-treated with 0.1 mg/kg of MK-801. A dose of 0.25 mg/kg substantially reduced confluent neuronal necrosis and the striatum and hippocampus were structurally preserved although reduced in size. It is noteworthy that this dose protected the cortex nearly completely and when damage was present it was usuaily confined to layer VI. Pre-treatment with 0.5 mg/kg ~MR-80f diminated the gross signs of NMDA nemotoxicity and reduced the glial response. Striatal size was reduced on the injected side with little change in hippocampal and cerebral hemisphere size. Myelinat-
0.1
ing fasicles within the striatum appeared to be relatively preserved.
MK-801 (1 mg/kg) also effectively antagonized NMDA toxicity when given 30, 40 or 120min after intrastriatal NMDA injections, MK-801 given after 30 or 40 mm totally prevented gross NMDA toxicity and when treatment was delayed for 2 h, the only h~stopa~holog~c changes were gliosis adjacent to the injection site and a slightly enlarged IateraI ventricle corresponding with a reduction in the size of the striatum on that side. Thus, the striatum, which receives the maximal dose of NMDA, was the only structure substantially damaged by NMDA in animals post-treated with MK-801 at 2 h. This pattern was similar to the distribution of injury in animals pre-treated with intermediate . The shrinkage in cross-sectional areas corresponded to the severity of the microscopic changes observed. NMRA caused a consistent loss of tissue cross-sectional area in the striatum (-59.6 + 3. I% decrease in the area of the injected hemisphere reiative to the opposite side), hippocampus (-50.3 2 3.1%) and cerebral hemisphere (-36.9 i 3.2%) on the lesioned side compared to the opposite side (P -c 0.001, paired t-test, n = 28). The size of the contralateral hemisphere of animals injected with NMDA was significantly reduced in comparison with that of sahne-injected controls; cross-sectional areas (mean + S.E.M.) of striatum were 6.50 + 0. I1 mm2 saline-injected, n = 5, vs 5.76 f 0.11 mm' NMDA-injected, n = 26, P < 0.005, one-way ANOVA. MK-801 treatment produced significant dose-dependent neuroprotection fP < 0.001, two-way ANUVA, MK-801~treated vs NMDA controls; n = 37, 28, respectively) with virtualiy 100% protection achieved in pups pre-treated with a 1 mg/kg MK-801 dose (Fig. 4) . Tissue damage was also evident in pups pre-treated with lower doses of MK-801; 0.5mg/kg or 0.25 mg/kg of MK-801 protected against 75 or 50% of tissue toss respectively in all three regions studied (P < 0.001, one-way ANOVA, MK-80Ltreated vs NMDA controls). At the lowest dose (0.1 mg~kg) the extent of damage in the striatum was nearly identical to that of controts, but there was significant neuroprotection in the hippocampus and a similar trend in the cerebral hemisphere (48 + 1 I %, P < 0.001 and 25 f 5% protection, respectivefy).
In animals treated with MK-801 at 30 or 40 min after NMDA injection, comparison of bilateral crosssectional areas demonstrated statisticahy significant neuronal protection in the hjppocampus and cerebral hemisphere ( Fig. 5 ; >90% protection, P -=z 0.001 one-way ANOVA, MK-801-treated, n = 10, vs NMDA controls, n = 28). MK-801 at these times was Cross-sectional areas of the striatum, hippocampus and cerebral hemisphere were measured bilaterally in four sections through each structure. In individual animals, values for each structure were summed by hemisphere and transformed by the formula (C -I)iC into a term reflecting the degree of damage of the injected hemjsphere. C and I refer to the cross-sectional areas of structures contralateral and ipsiiateral to the lesioned hemisphere. The data were expressed as percentage protection (mean + S.E.M.) for each experimental group using the formula given in Experimental procedures. "MK-801" groups received MK-801 prior to intrastriatal NMDA whereas "control" pups were administered saline. The shaded region represents the S.E.M. for the saline-treated NMDA-injected controls. All but the lowest dose of MK-801 produced significant neuroprotection in the striatum, the site of NMDA injection. Significant protection from NMDA-induced damage was also achieved by all doses of MK-801 in the hippocampus and cerebral hemisphere (P < 0.001, one-way ANOVA, MK-801 group vs saline-treated NMDA-injected controls). slightly less effective in the striatum, achieving 80 + 5% protection (P < 0.001). Even 2 h after the insult, the neuroprotective effects of MK-801 were substantial: 70 at 4% protection in the hippocampus and cerebral hemisphere, and 50 + 5% in the striaturn (P < 0.001, n = 6).
TIME EFFECT OF MK-
Quantitation of eflect of A4K-801 on quisqua/ate toxicit> MK-801 also provided some protection against quisqualic acid-induced neuronal injury (Fig. 6) . The cross-sectional areas on the lesioned side of quisqualic acid-treated pups were consistently reduced compared to the opposite side (striatum, -37.5 + 5.1%; hippocampus, -56.5 + 3.5; cerebral hemisphere, -11.5 + 3.7% P < 0.001, paired t-test, n = 4). It is noteworthy that the hippocampus was more susceptible to quisqualic acid-induced toxicity than was the striatum, whereas both are equally effected by NMDA. A 1 mg/kg dose of MK-801 administered i.p. twice, 30 min prior to and immediately after intrastriatal quisqualic acid injection (100 nmol/l .O pl), was significantly protective in the striatum (40 k 7%, protection, P < 0.02, independent t-test, MK-801"treated vs QA-injected controls) with a similar though not statistically significant trend observed in the cerebral hemisphere (56 f 19% protection). This dose was, however, less effective in the hippocampus (20 f 8% protection). A single dose of MK-801 has not been examined.
Egects of MK-801 and N-methyl-~-asFartate on behavioral and electroencephalogram activity
In saline-treated pups, intrastriatal NMDA injection caused turning behavior to the side of injection and increased locomotion within 20 min of initial recovery from ether anesthesia. Severe generalized, tonic and tonic-clonic seizures were evident 45 min after NMDA administration, an effect which typically endured for several hours. The seizures generally prevented an upright posture. MK-801 (1 mg/kg) blocked the behavioral signs of NMDAinduced seizures within 2-5min of i.p. administration. MK-801 pre-treatment facilitated induction and deepened the level of anesthesia produced by ether. Animals injected with MK-801 displayed a progressive set of behaviors. Initially, pups exhibited intermittent unidirectional turning and a general increase in locomotion. This behavior was still present 12 h after administration of MK-801 although it was less frequent. Following the initial period of behavioral excitation pups exhibited decreased muscle tone and a behavioral state of mild sedation. These effects were still present 24 h post-treatment, EEG recordings from saline-treated pups that received NMDA showed intermittent bihemispheric synchronous high-voltage, high-frequency epileptiform discharges. High-voltage and high-frequency discharges were present in the injected hemisphere at both 1 (n = 3) and 4 (n = 2) h post-NMDA EFFECT OF MK801 TREATMENT ON QUISQUALIC ACID NEUROTOXICITY Fig. 6 . Effect of MK-801. a non-competitive NMDA antagonist, on the neurotoxicity produced by intrastriatal injection of the glutamate receptor agonist quisqualic acid in seven-day-old rat pups (n = 6). MK-801 (1 mg/kg per dose) was administers i.p. 30 min before and immediately after injection of quisqualic acid (100 nmoI/l.O ~1). Data (mean + S.E.M.) were expressed as percentage protection (see Fig. 4 legend) and compared to saline-treated quisqualic acid-injected controls. The shaded bar is the S.E.M. for the quisquaIic acid-injected control group (n =4). MK-801 treatment produced significant protection against quisqualic acid-induced damage in the striatum (P 4 0.02, independent t-test, MK-8Ol-treated n = 6 vs saline-treated controls n = 4) with a similar trend in the cerebral hemisphere. In contrast, less protection was achieved in the hippocampus.
( Fig. 7) . EEGs from animals given either MK-801 alone (n = 5) or MK-801 plus NMDA {n = 5) showed marked voltage and frequency suppression (Fig. 7) . Few paroxysmal discharges were recorded in NMDA-treated pups that received MK-801.
DISCUSSION
The NMDA receptor is coupled to a cationic membrane channel at which activity is regulated by glycine, Mg*+, Zn2+ and phencyclidine receptor ligands.22~29~30@~43 NMDA receptor activation results in Ca*+, and Na*+ influx into the cell followed by passive Cl-influx. Excessive receptor activation results in intracellular Ca*+ accumulation, neuronal injury and death.4.5s'6.38,4' Unilateral injections of NMDA (25 nmol/0.5 yl) into the posterior striatum of seven-day-old rats produced a consistent and reproducible lesion characterized by confluent necrosis, gross tissue deformation, and reactive gliosis predominantly affecting the corpus striatum, dorsal hippo~mpus and overlying neocortex in the Iesioned hemisphere. This pattern of damage corresponds with NMDA receptor distributions within the immature brain (unpublished observations). Selectively vulnerable nuclei at the periphery of the lesion included the lateral septal, septofimbrial, thalamic and entopedunclular nuclei, areas which correspond to putative glutamatergic pathways and their terminal receptive fields.*.'*." The data demonstrate that syst~mi~ai~y administered MK-XOI prevents NINA-induced neuronal necrosis in the immature rat brain in a dose-dependent fashion (0.1--l mg/kg). Complete neuroprotection was achieved with a I m&kg MK-801 dose given i.p. 30 min prior to intrastriatal injection of 25 mnol NMDA. Near-complete protection was also achieved in animals post-treated with MK-801 (1 mg/kg, i.p.) 30 or 40tnin after intrastriatal NMDA injections. However, if the NMDA-induced events are allowed to proceed for 2 h prior to MK-801 treatment, substantial neuronat damage results. A 30% reduction is found in the cross-sectional area of the hippocampus and cerebral hemisphere of the injected hemisphere, and a 50% deerease is found in the striatum, the site of NMDA injection. This suggests that a critical time window exists in the evolution of NMDA-mediated injury within which treatment with MK-801 provides prote&on.
The dose of MK-801 required to achieve complete protection in the immature rat is considerably lower than the dose required to achieve complete protection in the adult rat brain as reported by Foster et al."
(1 vs 10 n-&kg). These findings, in addition to other reports, may indicate that non-competitive NMDA antagonists are more effective in the developing brains ' It is noteworthy that MK-801 also partially protected against quisqualic acid neurotoxicity. These findings were unexpected since MK-801 has been considered a selective NMDA antagonist, based on its failure to antagonize kainic acid-induced neuronal injury and kainic acid-and quisqualic acid-mediated electrophysiological responses in adult rat preparations.23*" MK-801 may attenuate quisqualic acidinduced brain damage by limiting secondary glutamate reiease and subs~uent activity of NMDA receptors. Although commercially available quisqualic acid may be contaminated with glutamate, intracerebral admi~ist~tion of glutamate (1 pmol) does not produce brain injury (unpublished observation). Thus, it is unlikely that exogenous glutamate contributes to quisqualic acid neurotoxiciiy in this model.
Interestingly, cortical layers IV and VI were destroyed with selective preservation of cortical layer V neurons in quisqualic acid-injected animals treated with MK-801. Similar results were occasionally found in pups that received only quisqualic acid, although less frequently. This observation may suggest that cells of cortical layers IV and VI have higher concentrations of quisqualic acid receptors.
Quisqualic acid-and NMDA-type EAA receptors may be involved in hypoxic-ischemic brain injury in immature rats, and the present data suggest that MK-801 may protect against both types of damage. At this age, kainate receptor-mediated damage probably contributes little damage directly in hypoxia-ischemia since kainic acid is not very neurotoxic at such an age.' High densities of quisqualic acid receptors are expressed transiently in vulnerable regions of immature mammaIian brain and direct injection of quisqualic acid into the seven-day-old rat brain causes neuronal damage and seizures.3,""6 The widespread neurQprotective effect of MK-801 in experimental hypoxia&hernia includes sites rich in quisqualic acid-preferring sites as well as those with a higher density of NMDA sites.
Neurotoxic effects of N-methyl-D-aspartate in developing versus adult brain
In comparison to reports describing NMDA neurotoxicity in adult rats, the developing CNS seems considerably more sensitive to NMDA toxicity.'4.33,sa Administration of 25 nmol of NMDA i~trastriatally in the seven-day-old rat produces confluent necrosis involving the entire cerebral hemisphere, resulting in a 37% decrease in the cross-sectional area five days later. In additional studies, a similar injection produced a 28% decrease in the weight of the injected hemisphere after similar delay." In contrast, we found that injections of 75 nmol/l.5 ~1 NMDA in adult rat striatum produced minimal neuronaf 597 damage without gross tissue deformation and destruction.33
The apparent developmental change in NMDA toxicity may reffect alterations in receptor numbers, ~ptor-ligand interaction, receptor-channel coupling, modulation of channel activation (e.g. by glyeine, Znz', Iv@+) or in the events leading to neuronal injury that may follow excessive NMDA receptor activation. h vitro autoradiographic studies indicate that NMDA and phencyclidine receptor binding is six-to eight-fold lower in seven-day-old rats in comparison to adults ~unpublished observation). There have been no reports indicating developmental changes in the coupling of the NMDA receptors to the channel, or in the mechanisms of channel regulation. Differences in the distribution, uptake, metabolism, and/or elimination of NMDA between immature and adult rats could account for part of the observed age-related effect. For example, the more heavily myelinated adult brain may limit diffusion. Furthermore, during the experimental period (7-12 days postnatal) the rat pups are undergoing rapid brain growth and this may alter the evolution of the lesion.
The relative ability of EAA agonists to produce neurotoxicity is also altered during development: the rank order of potency in aduft rat brain is kainic acid >> NMDA Z quisqualic acid, in contrast to NMDA B quisqualic acid >> kainic acid in sevenday-old rat brain. 2*9*2'*46.s5 Addit~onally~ quinol~nic acid, an NMDA receptor agonist, is a potent toxin in adult rats; however, it lacks neuronal toxicity in seven-day-old rats. I3 These age-related neurotoxic effects do not reflect simple alterations in ligand receptor numbers. For instance, NMDA receptor binding is reduced in vulnerable regions of the brain in seven-day-old rats compared to adults while quisqualic acid binding is about equivalent to that of adults.
Direct injection of NMDA into the seven-day-old rat brain provides a highly reproducible, convenient, quantiative system for evaluating potential neuroprotective drugs. Parallels of the model with experimental hy~xi~-isch~i~ brain injury suggest that compounds with neuroprotective activity in this preparation may also be active against ischemic neuronal necrosis. This model should also allow secondary metabolic effects of EAA neurotoxicity in the intact brain to be studied in isolation from pathogenetic models of hy~x~a-ischemia-mediated neuronal injury. 
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